Clinical trials: Metastatic Neoplasm
Melanoma
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
The primary purpose of this study is to assess the anti-tumor activity of LGX818/MEK162 in combination with targeted agents after progression on LGX818/MEK162 combination therapy, as well as the safety and tolerability of the…
- Trial name
- LOGIC-2 (NCT02159066)
- Testing
- LGX818, MEK162, LEE011
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 158 people
- Sponsor
- Pfizer
Breast Cancer, Cognitive/Functional Effects
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiation therapy can send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Lung Cancer, Metastatic Cancer
- Trial name
- NCT00377156
- Testing
- radiation therapy, stereotactic radiosurgery
- Where
- 64 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Undefined
Study on the Impact of a Modified Mediterranean Diet, in Patients With Colorectal Cancer Undergoing Active Medical Oncology Treatment
The study plans to evaluate the impact of the Modified Mediterranean Diet on the biodiversity of the intestinal microbiota (the set of physiological bacteria present at the intestinal level) in patients suffering from metastatic…
- Trial name
- MIC-1 (NCT06794931)
- Testing
- Nutrition, Biological samples collection
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda Socio Sanitaria della Brianza
Non-small Cell Lung Cancer
Fasting-mimicking Diet With Chemo-immunotherapy in Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment.
- Trial name
- NCT03700437
- Testing
- Fasting-Mimicking Diet
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Indiana University
Sarcoma
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
The main goal of this study is to test a new medicine, Risvutatug Rezetecan also called Ris-Rez. We want to see if this medicine can help people with certain types of cancer, whether its safe to use, how well people tolerate it…
- Trial name
- NCT07602777
- Testing
- Ris-Rez, G-CSF
- Where
- 13 sites in United States, Canada and 4 more
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline
Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started…
- Trial name
- NCT05411081
- Testing
- Atezolizumab, Biospecimen Collection, Bone Scan
- Where
- 198 sites in United States
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Metastases
Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
This trial will treat patients previously treated for advanced (metastatic) melanoma (skin cancer) with a new chemotherapeutic medicine.
- Trial name
- NCT00093119
- Testing
- ABI-007
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Celgene
Malignant Melanoma
Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28
Phase I/II clinical trial to analyze safety and efficiency of intralesional application of the bispecific single chain antibody rM28 and autologous PBMCs in patients with metastatic melanoma stage III/IV and unresectable…
- Trial name
- NCT00204594
- Testing
- rM28, autologous PBMCs
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- University Hospital Tuebingen
Metastatic Colorectal Cancer
Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer
The combination of oxaliplatin, 5-FU, leucovorin, and capecitabine is hypothesized to retain and potentially improve upon the activity of the FOLFOX regimens.
- Trial name
- NCT00205322
- Testing
- chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Wisconsin, Madison
Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3
Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
This phase II trial studies how well atezolizumab works in treating patients with chondrosarcoma or clear cell sarcoma that is newly diagnosed, cannot be removed by surgery (unresectable), or has spread to other places in the…
- Conditions
- Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma, Metastatic Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT04458922
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 15 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer
This was a Phase II, open-label, prospective, multicenter study designed to evaluate the efficacy and safety of single-agent atezolizumab as a first-line therapy in participants with locally advanced or metastatic non-small cell…
- Trial name
- B-F1RST (NCT02848651)
- Testing
- Atezolizumab
- Where
- 20 sites in United States
- Volunteers
- 153 people
- Sponsor
- Genentech, Inc.
Locally Advanced Solid Tumor
Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors
This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced/metastatic solid tumors.
- Trial name
- NCT06658353
- Testing
- VC004 Capsules
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Squamous Cell Carcinoma of the Skin
Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin
To determine the Objective Response Rate (ORR) of immunotherapy with Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in patients with locally advanced/metastatic squamous cell carcinoma of the skin using Response…
- Trial name
- NCT04204837
- Testing
- Nivolumab, Nivolumab plus Relatlimab
- Where
- 7 sites in Austria
- Volunteers
- 61 people
- Sponsor
- Salzburger Landeskliniken
Lung Cancer, Neurotoxicity
Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more tumor cells.
- Conditions
- Lung Cancer, Neurotoxicity, Ovarian Cancer
- Trial name
- NCT00003072
- Testing
- amifostine trihydrate, carboplatin, paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of California, San Francisco
Secondary or Tertiary Peritonitis
Procalcitonin as a Marker for the Length of Antibiotic Treatment in Peritonitis and Intra-abdominal Infections
Procalcitonin level used for determining length of antibiotic treatment in peritonitis and intra-abdominal infections. Hypothesis is that length of antibiotic use can be shortened by this method.
- Trial name
- NCT01155739
- Where
- Switzerland
- Volunteers
- 162 people
- Sponsor
- University of Lausanne Hospitals
Non-Small Cell Lung Cancer, Carcinoma
MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC
This first time in human study is intended for men and women at least 18 years of age who have advanced lung cancer which has grown or returned after being treated.
- Trial name
- NCT02592577
- Testing
- Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 28 people
- Sponsor
- Adaptimmune
Pancreatic Cancer
Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00042939
- Testing
- cetuximab, docetaxel, irinotecan hydrochloride
- Volunteers
- 94 people
- Sponsor
- Eastern Cooperative Oncology Group
Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma
Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer
Single-arm, open-label, multicenter phase 2 clinical trial evaluating the clinical and the immunological activity of an innovative strategy with an induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a…
- Conditions
- Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma, Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
- Trial name
- CombiCoR-Vax (NCT06522919)
- Testing
- Autologous Dendritic Cell (DC) Vaccine
- Where
- 2 sites in Italy
- Volunteers
- 36 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Colo-rectal Cancer
The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts
This is an open label, multicenter, randomized study in Chinese patients with RAS and BRAF wild-type mCRC. Participants were randomly assigned to cetuximab + FOLFOX (group A) and cetuximab + modified XELOX[mXELOX] (group B).
- Trial name
- NCT05074966
- Testing
- Experimental: mXELOX plus cetuximab, Active Comparator: FOLFOX plus cetuximab
- Where
- China
- Volunteers
- 314 people
- Sponsor
- Chinese Academy of Medical Sciences
Metastatic Colorectal Cancer
Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR
patients with metastatic colorectal cancer who were initially RAS wild and failed at least 2 lines of chemotherapy will be enrolled. Anti-EGFR must have been given in 1st line.
- Trial name
- REPAN (NCT03940131)
- Testing
- Panitumumab
- Where
- Saudi Arabia
- Volunteers
- 30 people
- Sponsor
- King Abdullah Medical City
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.